Research programme: anti-angiomotin antibodies - BioInventAlternative Names: Angiomotin monoclonal antibody; Cancer antibodies - BioInvent; n-CoDeR anti Angiomotin
Latest Information Update: 09 Jul 2014
At a glance
- Originator Karolinska Institute; Servier
- Developer BioInvent International; Servier
- Class Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer